Midomafetamine for stress disorders, post-traumatic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 18 registered trials.

Why this status

  1. 4 Sep 2019: Trial registered, NCT04077437
  2. 2 Sep 2020: Trial started, NCT04077437

The trials

NCT00353938: Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

State
Completed
Phase
Phase 2
People
14 taking part
Started
13 Sep 2006
Primary completion
2 Sep 2009
Arms
Full Dose MDMA-assisted therapy (125 mg)
Results
Posted on the registry
  1. 19 Jul 2006: Trial registered
  2. 13 Sep 2006: Trial started
  3. 10 Jan 2011: Trial completed
  4. 16 Sep 2021: Trial results posted

NCT01211405: Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

State
Completed
Phase
Phase 2
People
26 taking part
Started
10 Nov 2010
Primary completion
4 Jun 2015
Arms
Full dose MDMA-assisted therapy
Results
Posted on the registry
  1. 29 Sep 2010: Trial registered
  2. 10 Nov 2010: Trial started
  3. 2 Aug 2016: Trial completed
  4. 2 Feb 2022: Trial results posted

NCT01689740: Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

State
Completed
Phase
Phase 2
People
10 taking part
Started
17 Jan 2013
Primary completion
7 Apr 2016
Arms
Lead in: 125 mg MDMA-assisted therapy (Open-Label), Full dose MDMA-assisted therapy (125 mg)
Results
Posted on the registry
  1. 21 Sep 2012: Trial registered
  2. 17 Jan 2013: Trial started
  3. 16 Jul 2017: Trial completed
  4. 30 Oct 2020: Trial results posted

NCT01793610: Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

State
Completed
Phase
Phase 2
People
29 taking part
Started
13 May 2013
Primary completion
3 Dec 2015
Arms
Active Dose 2 (100 mg) MDMA-assisted therapy, Active Dose 1 (125 mg) MDMA-assisted therapy
Results
Posted on the registry
  1. 15 Feb 2013: Trial registered
  2. 13 May 2013: Trial started
  3. 1 Feb 2017: Trial completed
  4. 14 Oct 2020: Trial results posted

NCT03752918: The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

State
Withdrawn before it started
Phase
Phase 1
People
0 taking part
Started
May 2024
Primary completion
Jan 2028
Arms
MDMA
Results
None posted
  1. 26 Nov 2018: Trial registered
  2. 19 May 2026: Trial withdrawn

NCT04077437: A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

State
Completed
Phase
Phase 3
People
121 taking part
Started
2 Sep 2020
Primary completion
30 Oct 2022
Arms
Experimental: MDMA-assisted psychotherapy
Results
Posted on the registry
  1. 4 Sep 2019: Trial registered
  2. 2 Sep 2020: Trial started
  3. 2 Nov 2022: Trial completed
  4. 11 Oct 2023: Trial results posted

NCT04264026: MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

State
Completed
Phase
Phase 2
People
5 taking part
Started
29 Jul 2021
Primary completion
1 May 2025
Arms
Open Label
Results
None posted
  1. 11 Feb 2020: Trial registered
  2. 29 Jul 2021: Trial started
  3. 1 May 2025: Trial completed

NCT05067244: A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

State
Completed
Phase
Phase 2
People
10 taking part
Started
4 Oct 2021
Primary completion
1 Nov 2024
Arms
MDMA assisted psychotherapy
Results
None posted
  1. 4 Oct 2021: Trial started
  2. 5 Oct 2021: Trial registered
  3. 1 Nov 2024: Trial completed

NCT05455996: MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders

State
Not started
Phase
Phase 2
People
30 planned
Started
Oct 2026
Primary completion
Jan 2028
Arms
MDMA-assisted therapy
Results
None posted
  1. 13 Jul 2022: Trial registered

NCT05732155: Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD

State
Under way
Phase
Phase 2
People
60 planned
Started
1 Jun 2023
Primary completion
1 Jun 2027
Arms
MDMA-assisted therapy
Results
None posted
  1. 16 Feb 2023: Trial registered
  2. 1 Jun 2023: Trial started

NCT05746572: MDMA Plus Exposure Therapy for PTSD

State
Under way
Phase
Phase 2
People
40 planned
Started
13 Feb 2024
Primary completion
31 Oct 2026
Arms
Medicine Session
Results
None posted
  1. 27 Feb 2023: Trial registered
  2. 13 Feb 2024: Trial started

NCT05790239: MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

State
Under way
Phase
Phase 2
People
40 planned
Started
1 Mar 2025
Primary completion
Mar 2028
Arms
MDMA-Assisted Therapy
Results
None posted
  1. 30 Mar 2023: Trial registered
  2. 1 Mar 2025: Trial started

NCT05943665: MDMA for AUD/PTSD Comorbidity

State
Completed
Phase
Phase 2
People
22 taking part
Started
6 Feb 2024
Primary completion
21 Jan 2026
Arms
MDMA-AT
Results
None posted
  1. 13 Jul 2023: Trial registered
  2. 6 Feb 2024: Trial started
  3. 30 Jan 2026: Trial completed

NCT06044675: MDMA-Assisted CBCT for PTSD vs CBCT RCT

State
Under way
Phase
Phase 2
People
60 planned
Started
15 Nov 2024
Primary completion
31 Mar 2027
Arms
MDMA-Assisted CBCT Condition
Results
None posted
  1. 21 Sep 2023: Trial registered
  2. 15 Nov 2024: Trial started

NCT07118839: MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

State
Under way
Phase
Phase 2 and Phase 3
People
80 planned
Started
18 May 2026
Primary completion
1 May 2030
Arms
Full dose MDMA-Assisted Therapy
Results
None posted
  1. 12 Aug 2025: Trial registered
  2. 18 May 2026: Trial started

NCT07288151: MDMA-Assisted Massed Exposure Therapy for PTSD

State
Under way
Phase
Phase 2
People
200 planned
Started
Jul 2026
Primary completion
Jan 2030
Arms
MDMA group
Results
None posted
  1. 17 Dec 2025: Trial registered

NCT07569159: MDMA Therapy in Veterans With PTSD

State
Under way
Phase
Phase 2
People
52 planned
Started
30 Jun 2026
Primary completion
1 Apr 2027
Arms
Individual, Group
Results
None posted
  1. 6 May 2026: Trial registered

NCT07765693: MDMA-AT for PTSD in Young Adults With Childhood Trauma

State
Not started
Phase
Phase 2
People
15 planned
Started
31 Oct 2026
Primary completion
30 Jan 2028
Arms
Experimental: MDMA-AT for PTSD
Results
None posted
  1. 14 Aug 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as 3,4 Methylenedioxymethamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxymethamphetamine (125 mg), Active Dose 1 (125 mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Full Dose MDMA, Full Dose MDMA-assisted therapy (125 mg), Full dose MDMA-assisted therapy, Mdma, MDMA assisted psychotherapy, Open-Label Full Dose MDMA-assisted therapy (125 mg), methylenedioxymethamphetamine.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.